Treatment Trials

4 Clinical Trials for Various Conditions

Focus your search

      WITHDRAWN
      Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma
      Description

      This phase II clinical trial studies how well giving brentuximab vedotin together with pembrolizumab in treating patients with peripheral T-cell lymphoma (PTCL) that has come back (recurrent). Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells. Pembrolizumab is an antibody-drug that stimulates body's natural antitumor immune responses. Giving brentuximab vedotin together with pembrolizumab may work better than brentuximab vedotin alone in treating patients with recurrent peripheral T-cell lymphoma.

      Conditions
      Recurrent Angioimmunoblastic T-Cell LymphomaRecurrent Enteropathy-Associated T-Cell LymphomaRecurrent Follicular T-Cell LymphomaRecurrent Hepatosplenic T-Cell LymphomaRecurrent Nodal Peripheral T-Cell Lymphoma With TFH PhenotypeRecurrent Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Subcutaneous Panniculitis-Like T-Cell LymphomaRefractory Angioimmunoblastic T-Cell LymphomaRefractory Enteropathy-Associated T-Cell LymphomaRefractory Follicular T-Cell LymphomaRefractory Hepatosplenic T-Cell LymphomaRefractory Nodal Peripheral T-Cell Lymphoma With TFH PhenotypeRefractory Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedRefractory Subcutaneous Panniculitis-Like T-Cell Lymphoma
      Talk to us
      COMPLETED
      Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma
      Description

      This pilot clinical trial studies Salvia hispanica seed in reducing the risk of returning disease (recurrence) in patients with non-Hodgkin lymphoma. Functional foods, such as Salvia hispanica seed, has health benefits beyond basic nutrition by reducing disease risk and promoting optimal health. Salvia hispanica seed contains essential poly-unsaturated fatty acids, including omega 3 alpha linoleic acid and omega 6 linoleic acid; it also contains high levels of antioxidants and dietary soluble fiber. Salvia hispanica seed may raise omega-3 levels in the blood and/or change the bacterial populations that live in the digestive system and reduce the risk of disease recurrence in patients with non-Hodgkin lymphoma.

      Conditions
      Adult Nasal Type Extranodal NK/T-Cell LymphomaAdult T-Cell Leukemia/LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-Cell LymphomaB Lymphoblastic Leukemia/LymphomaBlastic Plasmacytoid Dendritic Cell NeoplasmBurkitt LeukemiaCentral Nervous System LymphomaChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaDiffuse Large B-Cell LymphomaEnteropathy-Associated T-Cell LymphomaExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3 Follicular LymphomaHepatosplenic T-Cell LymphomaLymphoplasmacytic LymphomaMantle Cell LymphomaMediastinal (Thymic) Large B-Cell LymphomaMycosis FungoidesNasal Type Extranodal NK/T-Cell LymphomaNodal Marginal Zone LymphomaPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedPost-Transplant Lymphoproliferative DisorderPrimary Cutaneous Anaplastic Large Cell LymphomaPrimary Effusion LymphomaSezary SyndromeSplenic Marginal Zone LymphomaSubcutaneous Panniculitis-Like T-Cell LymphomaSystemic Anaplastic Large Cell LymphomaT Lymphoblastic Leukemia/LymphomaTransformed Recurrent Non-Hodgkin Lymphoma
      Talk to us
      ACTIVE_NOT_RECRUITING
      Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
      Description

      This phase I/II trial studies the side effects and best dose of pralatrexate when given together with pembrolizumab and how well they work in treating patients with peripheral T-cell lymphomas that has come back after a period of improvement or has not responded to treatment. Pralatrexate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab and pralatrexate may work better in treating patients with peripheral T-cell lymphomas.

      Conditions
      Anaplastic Large Cell LymphomaNodal Peripheral T-Cell Lymphoma With TFH PhenotypeRecurrent Anaplastic Large Cell LymphomaRecurrent Angioimmunoblastic T-Cell LymphomaRecurrent Enteropathy-Associated T-Cell LymphomaRecurrent Follicular LymphomaRecurrent Hepatosplenic T-Cell LymphomaRecurrent Mature T- Cell and NK-Cell Non-Hodgkin LymphomaRecurrent Monomorphic Epitheliotropic Intestinal T-cell LymphomaRecurrent Mycosis FungoidesRecurrent Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedRefractory Anaplastic Large Cell LymphomaRefractory Angioimmunoblastic T-Cell LymphomaRefractory Enteropathy-Associated T-Cell LymphomaRefractory Follicular LymphomaRefractory Hepatosplenic T-Cell LymphomaRefractory Mature T-Cell and NK-Cell Non-Hodgkin LymphomaRefractory Mycosis FungoidesRefractory Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedSubcutaneous Panniculitis-Like T-Cell Lymphoma
      Talk to us
      TERMINATED
      Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
      Description

      RATIONALE: Everolimus and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus when given together with bortezomib in treating patients with relapsed or refractory lymphoma.

      Conditions
      714leukemiaLymphoma
      Talk to us